The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice.
 
Debra L. Richardson
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Immunogen; Mersana
Research Funding - Aravive (Inst); Arch Oncology (Inst); ArQule (Inst); AstraZeneca (Inst); Celsion (Inst); Clovis Oncology (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Innovent Biologics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Plexxikon (Inst); Roche (Inst); Shattuck Labs (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
 
Julia C. F. Quintanilha
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - United States Patent: "Methods of identifying risk of bevacizumab-induced proteinuria and hypertension", Innocenti F., Quintanilha J., Lin D., Owzar K., Wang J. Filed on July 17, 2020, serial number 16/932002; United States Provisional Patent Application: "Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab induced hypertension", Innocenti F., Quintanilha J. Filed on April 1, 2021, serial number 63/169301
Travel, Accommodations, Expenses - Foundation Medicine
 
Ryon Graf
Employment - Epic Sciences; Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Epic Sciences; Foundation Medicine
 
Natalie Danziger
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Christina Washington
Consulting or Advisory Role - Immunogen
 
Lauren E. Dockery
No Relationships to Disclose
 
Tamara Snow
Employment - Flatiron Health
Stock and Other Ownership Interests - Flatiron Health; Roche
 
Anosheh Afghahi
Employment - Flatiron Health
 
Anthony Frachioni
Employment - Flatiron Health
 
Julia A Elvin
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Kathleen N. Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - AADi; Alkermes (Inst); AstraZeneca; Blueprint Medicines (Inst); Caris Life Sciences; Clovis Oncology; Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); Hengrui Pharmaceutical; I-Mab (Inst); Immunogen; InxMed (Inst); Iovance Biotherapeutics; Merck; Mereo BioPharma; Mersana (Inst); Myriad Genetics; Novartis; Novartis/Pfizer; Onconova Therapeutics; OncXerna Therapeutics; VBL Therapeutics; Verastem/Pharmacyclics
Research Funding - Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline
Other Relationship - GOG Partners (Inst)